Trials / Recruiting
RecruitingNCT05839392
Novel Approaches to Target MECOM/EVI1 in AML
Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Detailed description
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Biological characterization of AML with MECOM or atypical 3q26 rearrangements | Peripheral blood and bone marrow withdrawal |
Timeline
- Start date
- 2023-12-13
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2023-05-03
- Last updated
- 2023-12-29
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05839392. Inclusion in this directory is not an endorsement.